TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06402110

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Femoral Triangle Block
Description: Patients will receive femoral triangle block (FTB) at the end of surgery. The probe will be positioned at the level where the medial border of the sartorius muscle intersects the medial border of the adductor longus muscle, a block needle advanced in an in-plane technique into femoral triangle. After negative aspiration, 2ml of saline will be injected to confirm the needle tip position close to the femoral artery then injection of 15ml of bupivacaine 0.25% will be performed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adductor Canal Block
Description: Patients will receive adductor canal block (ACB) at the end of surgery. The probe will be positioned at the point midway between the anterior superior iliac spine and the upper pole of the patella. The adductor canal will be located as a hyperechoic structure beneath the Sartorius muscle and a block needle advanced in an in-plane technique toward the target nerve after negative aspiration, 2ml of saline will be injected into adductor canal to confirm the block needle tip within it, the block needle will be advanced with the guidance of ultrasound in an in-plane technique and 15ml bupivacaine 0.25% will be injected.
Study: NCT04790734

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sedation drugs
Description: Different sedation drugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sedation drugs
Description: Different sedation drugs
Study: NCT06136910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human adenovirus type 5 injection (H101) combined with tirilizumab and platinum-containing two-drug chemotherapy
Description: 1. Recombinant human adenovirus type 5 injection : 21 days is one treatment cycle, in principle, 4 cycles of administration, 1 injection on day 1 (d1) of each cycle; the number of injections is determined according to the patient's tolerance and the ease of operation of the injection site, no less than 2 times.~2. tirelizumab: 200mg intravenous, d1, Q21d, administered until disease progression or intolerable side effects occur~3. platinum-containing two-drug chemotherapy: adenocarcinoma, pemetrexed combined with carboplatin, 4-6 cycles, d2, Q21d; non-adenocarcinoma, paclitaxel/gemcitabine combined with carboplatin, 4-6 cycles, d2, Q21d.
Study: NCT05298410

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Limitless
Description: Participants will be instructed to take Limitless for 30 days.
Study: NCT05885906

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aloevera
Description: Mouthwash

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thyme honey
Description: Mouthwash
Study: NCT06394297

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT to reproduce HDR BT dose distribution in non-operated patients LACC
Study: NCT04711044

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Papain
Description: Papain will be applied using cowhage spicules inactivated by heat

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Histamine
Description: To deliver histamine, standard allergy skin prick test (SPT) lancets are applied

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cowhage
Description: Cowhage spicules are 1-2 mm in length and have a diameter of 1-3 μm. The spicules are inserted by gently rubbing 30-35 spicules into a 1 cm diameter skin area.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: L-menthol
Description: A 1 mL aliquot is dispensed onto a 2,5 × 2,5 cm cotton pad and placed on a 6 × 6 cm sheet of medical tape.
Study: NCT05885906

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Mouthwash
Study: NCT04988087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MHV370
Description: MHV370 for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MHV370
Description: MHV370 for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 24 weeks
Study: NCT06229730

Intervention type: DIAGNOSTIC_TEST
Intervention: video Head Impulse Test
Description: For v-HIT, the Synapsys v-HIT Ulmer device is used.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cervical Vestibular Evoked Myogenic Potential
Description: For cVEMP, the Eclipse (Interacoustic, Middelfart, Denmark) is used. To bypass the frequent middle ear problems bone conduction stimuli (B-81, Interacoustic, Middelfart, Denmark) are administrated. The bone conductor is placed on the mastoid process and two trials at 70 dB nHL are conducted to check waveform reproducibility. 500 Hz short tone bursts (2-2-2 ms) are applied at 5 per second stimulus repetition rate.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ocular Vestibular Evoked Myogenic Potential
Description: For oVEMP, the Eclipse (Interacoustic, Middelfart, Denmark) is used. To bypass the frequent middle ear problems bone conduction stimuli (B-81, Interacoustic, Middelfart, Denmark) are administrated. The bone conductor is placed on the mastoid process and two trials at 70 dB nHL are conducted to check waveform reproducibility. 500 Hz short tone bursts (2-2-2 ms) are applied at 5 per second stimulus repetition rate.
Study: NCT04988087

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 24 weeks
Study: NCT05822258

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walk under 3 conditions (normal, physical tasks, verbal tasks)
Description: Each patient will have 2 visits :~* First visit in the ON state phase, i.e. when their oral treatment allows the maximum improvement of dopamine-responsive parkinsonian symptoms.~* A second visit will be scheduled 15 +/- 7 days from the first. Patients will then be assessed in the OFF phase after having stopped taking their antiparkinsonian medications for at least 12 hours before the start of the visit, in order to promote episodes of FOG~For each visit, the patient will be asked to walk at a comfortable speed under the following 3 conditions:~* Normal condition without addition of additional physical and verbal tasks~* Condition with added physical tasks: The physical task of holding a ball in the center of a tray~* Condition with added verbal tasks: The verbal task of saying as many words as possible starting with a specific letter.~Conditions of passage are randomized per patient. Each subject will complete the course a maximum of 18 times in blocks of 3 conditions.
Study: NCT06634017

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Platelet rich fibrin
Description: Only the test side that will be intervened with i-PRF will be obtained from the upper liquid layer and will be placed in dental injectors using a 27 mm gauged needle. During the first application the amount of i-PRF will be standardized as 4 mL and injected through intra-ligamental into the disto-buccal and disto-palatal side of the canine tooth (2 mL for each side) and at the time of second intervention i.e 8th week form the baseline intramucosal injection will be administered equidistant from the maxillary canine and second premolar, 2ml on buccal side and 2ml on palatal side) after anesthetizing the region with local anesthesia (2% Lignocaine).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet rich fibrin
Description: Only the test side that will be intervened with i-PRF will be obtained from the upper liquid layer and will be placed in dental injectors using a 27 mm gauged needle. During the first application the amount of i-PRF will be standardized as 4 mL and injected through intra-ligamental into the disto-buccal and disto-palatal side of the canine tooth (2 mL for each side) and at the time of second intervention i.e 8th week form the baseline intramucosal injection will be administered equidistant from the maxillary canine and second premolar, 2ml on buccal side and 2ml on palatal side) after anesthetizing the region with local anesthesia (2% Lignocaine).
Study: NCT06437574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vytorin
Description: Vytorin is a drug combination (Ezetimibe and Simvastatin) that targets the two primary sources of cholesterol, absorption in the gut and synthesis in the liver.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Ezetimibe is a drug that targets one of the primary sources of cholesterol, absorption in the gut.
Study: NCT04820530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iptacopan (LNP023)
Description: Taken orally b.i.d. Dosage supplied: 200mg Dosage form: Hard gelatin capsule Route of Administration: oral
Study: NCT05597735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tecovirimat
Description: The experimental intervention is tecovirimat, available as immediate-release capsules containing tecovirimat monohydrate, equivalent to 200 mg of tecovirimat. The route of administration of tecovirimat is oral. Tecovirimat treatment will be initiated as soon as possible after diagnosis.~The international recommended doses will be followed:~* 25 kg to less than 40 kg: 400 mg (two tecovirimat 200 mg capsules) every 12 hours for 14 consecutive days.~* 40 kg and above: 600 mg (three tecovirimat 200 mg capsules) every 12 hours for 14 consecutive days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control intervention is a placebo and its route of administration will be identical to the experimental intervention administration to allow treatment arm blinding.
Study: NCT06504849

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Receiving LSM messages.
Description: * LSM messages via instant messaging applications~* Chat-type support messages via instant messaging applications

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Receiving brief pre-HTN messages.
Description: * A flyer with brief pre-HTN information which is distributed during the recruitment phase~* Brief pre-HTN messages via instant messaging applications
Study: NCT06229730

Intervention type: DIAGNOSTIC_TEST
Intervention: Computerized Dynamic Posturography
Description: To evaluate functional balance of the children and the relative contributions of the vision, proprioception, and vestibular system a CDP from Virtualis (Virtualis, Montpellier, France) is used.

Intervention type: OTHER
Intervention: Dizziness Handicap Inventory for patient caregivers
Description: DHI is a caregiver-reported 21-item questionnaire. It is designed to evaluate the perceived quality of life and handicap resulting from dizziness and unsteadiness for the pediatric population. For each question there are three possible answers: yes, sometimes or no. Each answer provides respectively 4, 2 and 0 points. The total DHI scores range from 0 to 84 with higher score being consistent with more limitation and more severe handicap. Scores under 16 are characterized as no limitation or handicap. A score from 16-26 present a mild perceived handicap and mild limitations. A DHI-score between 26-43 is classified as a moderate problem, and a score above 43 describes a severe perceived handicap and severe limitations.
Study: NCT04878848

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation Exercises
Description: Within the scope of proprioceptive neuromuscular facilitation exercises, rhythmic initiation, repeated stretch and hold-relax techniques in the upper extremity flexion-abduction-external rotation pattern and scapular patterns of anterior elevation, posterior depression, anterior depression and posterior elevation will be applied to the participants. In addition to these exercises, functional activities in the flexion-abduction-external rotation pattern such as hair combing, turning over from side lying, wearing a jacket, reaching on the shelf will be performed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Rehabilitation Group
Description: Active assisted / active range of motion exercises and Wand exercises will be applied to the participants in the conventional rehabilitation group for flexion, abduction and external rotation movements. Exercises will be applied as 5 repetitions in the first 2 weeks and 10 repetitions in the last 2 weeks. Strengthening exercises will be performed with an elastic band and free weights. Strengthening exercises will be started as 2 sets of 5 repetitions and at the end of the second week, it will be applied as 2 sets of 10 repetitions. In addition to these exercises, glenohumeral distraction, glenohumeral posterior and caudal glide will be applied for joint mobilization and it will show progression at the end of the second week.
Study: NCT06453135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: On the Day 0, participants received a single dose of eculizumab before the transplant surgery: 900 mg (blood type antibody titer ≥ 1:64 and/or body weight ≥ 60 kg) or 600 mg (blood type antibody titer \< 1:64 and body weight \< 60 kg). Plasmapheresis was not planned. When participants developed AMR, they may receive additional dose of eculizumab.
Study: NCT05336383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Given by Infusion
Study: NCT05312320

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Information film
Description: * Sexual activity after MI does not increase risk of recurrence or death~* Sexual activity is associated with improved outcome after MI~* Resuming sexual activity as normal is recommended and completely safe
Study: NCT06462560

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vivo Online Exercise Program
Description: Virtual online exercise programs conducted by the Vivo team consisting of multiple time a week group live programs

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medbridge Home program
Description: At home exercise program accessed through exercise descriptions and short vidoes
Study: NCT06370650

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: platelet rich plasma, narrow band UVB
Description: Role of PRP in treating stable vitiligo

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: platelet rich plasma, narrow band UVB
Description: Role of PRP in treating stable vitiligo
Study: NCT06285032

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Controlled Group
Description: Those randomized to the control group will receive usual care from their primary care clinician. At the conclusion of the study (after the final outcomes are collected), they will be offered a list of possible community-based organizations for social connection.
Study: NCT04698460

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hybrid coronary revascularization
Description: A staged procedure with a minimally invasive direct coronary artery bypass grafting of left anterior descending artery by left internal mammary artery (LIMA-LAD MIDCAB) at first stage, and percutaneous stenting of iFR-significant lesions in non-LAD arteries at the second stage
Study: NCT05102344

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Social Skills Training
Description: Behavioral Social Skills Training treatment as usual will include small group semi-structured play, didactic instruction and role-play of basic social skills, including assertion, ignoring provocation, accepting consequences, problem solving, following directions, and self-regulation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animal Assisted Intervention
Description: Behavioral Social Skills Training treatment as usual will include small group semi-structured play, didactic instruction and role-play of basic social skills, including assertion, ignoring provocation, accepting consequences, problem solving, following directions, and self-regulation accompanied by trained therapy dogs
Study: NCT04698460

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary artery bypass grafting
Description: A conventional procedure of median thoracotomy with on-pump bypass grafting of left anterior descending artery by left internal mammary artery and saphenous vein grafting of circumflex and/or right coronary artery
Study: NCT05363618

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Panosyl-isomaltooligosaccharides (PIMO) 1g (1.4 ml)
Description: Active study product

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 1.4 ml
Description: Placebo
Study: NCT06296043

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation Exercise Group
Description: Exercise Group

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Su-Jok Intervention
Description: Hand massage with seeds
Study: NCT06412640

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Keverprazan
Description: Potassium-competitive acid blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keverprazan
Description: Potassium-competitive acid blocker

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Antibiotic for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Antibiotic for H. pylori eradication
Study: NCT06247475

Intervention type: OTHER
Intervention: Answers generated by ChatGPT
Description: Participants will assign a satisfaction score based on the appropriateness of each answer.
Study: NCT06089863

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PAMPERO program
Description: This program is an intensive multidisciplinary program rehabilitation including Physical, Occupational, Speech, Psychomotor therapy and Adapted Physical Activity. The duration of this program is 5 weeks and each week is divided as follow :~* 5 hours of physical therapy : individual session with the objective to improve the dynamic balance and coordination on the aim to gain confidence of moving, gripping capacity and interaction with object~* 5 hours of Adapted Physical activity : group session to promote pairing with muscle building priority~* 1 hour of Speech therapy : group session to educate and promote prevention strategy about dysphagia rick~* 2 hours of Occupational therapy : group session to bring adaptive solution of autonomy lost with material propose, home organisation or gesture~* 2 hours of Hydrotherapy : group session activity performed in water to assist rehabilitation
Study: NCT06169787

Intervention type: PROCEDURE
Intervention: sentinel lymph node biopsy
Description: sentinel lymph node biopsy
Study: NCT06247475

Intervention type: OTHER
Intervention: Answers generated by ChatGPT
Description: Participants will assign a satisfaction score based on the appropriateness of each answer.

Intervention type: OTHER
Intervention: Answers generated by ChatGPT
Description: Participants will assign a satisfaction score based on the appropriateness of each answer.

Intervention type: OTHER
Intervention: Answers generated by ChatGPT
Description: Participants will assign a satisfaction score based on the appropriateness of each answer.
Study: NCT06169787

Intervention type: PROCEDURE
Intervention: comprehensive pelvic lymphadenectomy
Description: comprehensive pelvic lymphadenectomy
Study: NCT05672641

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inertial training
Description: Inertial training group performed their training three times a week (Monday, Wednesday, and Friday) between between 7:00 a.m. and 8:30 a.m. for 6 weeks. Participants performed inertial training using Cyklotren (Inerion, Poland). Before each training session, a standardized warm-up was performed. Each session trained two muscle groups: elbow flexors and knee extensors. Each exercise included 3 sets, with the right and left extremities worked separately. In each set 12 repetitions were performed. A 2-minute break occurred between consecutive sets. Each exercise for elbow flexors was performed in standing position. Each exercise for knee extensors was performed in seated position in a bench. The range of motion for elbow flexors was approximately 130 degrees and for knee extensors was approximately 80 degrees.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body building training
Description: Body building group performed body building training three times a week (Monday, Wednesday, and Friday) between 7:00 a.m. and 8:30 a.m. for 6 weeks using free weights. Before each training session, a standardized warm-up was performed. Each session trained two muscle groups: elbow flexors and knee extensors. Each exercise included 3 sets, with the right and left extremities worked separately. In each set 12 repetitions were performed. A 2-minute break occurred between consecutive sets. Each exercise for elbow flexors was performed in standing position. Each exercise for knee extensors was performed in seated position in a bench. The range of motion for elbow flexors was approximately 130 degrees and for knee extensors was approximately 80 degrees.
Study: NCT05961241

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: runnin training program
Description: gradual training program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: runnin training program
Description: gradual training program
Study: NCT04699695

Intervention type: OTHER
Intervention: Biologic therapy versus no biologic therapy
Description: Biologic therapy administered per standard of care

Intervention type: OTHER
Intervention: Biologic therapy versus no biologic therapy
Description: Biologic therapy administered per standard of care
Study: NCT04908384

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improving Asthma Care Together (IMPACT)
Description: IMPACT is a novel health application and wearable device
Study: NCT05307965

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Retriever Thrombectomy
Description: The SolitaireTM X revascularisation device is a self-expanding stent designed for dynamic clot integration with radiopaque markers that enhance visualisation of the optimal working length. After a thrombotic occlusion has been identified and crossed with a guidewire, the stent-retriever thrombectomy proceeds. A microcatheter (e.g., PhenomTM, MarksmanTM) is advanced over the guidewire and once it has traversed the thrombotic occlusion, the SolitaireTM X device is advanced through the microcatheter until the usable length of the stent extends past each side of the thrombus in the vessel. As the microcatheter is retracted to the proximal radiopaque marker of the stent, the stent self-expands and entangles the thrombus. The microcatheter and SolitaireTM X Revascularisation Device are withdrawn as a unit into the guide catheter under continuous aspiration. PCI then proceeds driven by clinical decision making and department guidelines.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention
Description: Standard of care

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention
Description: Standard of care

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention
Description: Standard of care

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thrombus Aspiration
Description: Standard of care treatment with manual thrombectomy catheter